# Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration

> **NCT03744767** · PHASE2 · COMPLETED · sponsor: **Dr Irmela MANTEL** · enrollment: 20 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Spironolactone 50 MG

## Key facts

- **NCT ID:** NCT03744767
- **Lead sponsor:** Dr Irmela MANTEL
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-19
- **Primary completion:** 2015-09-22
- **Final completion:** 2015-09-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03744767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03744767, "Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03744767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*